Early Stages of Mesothelioma

During the early stages of mesothelioma, the cancer is contained in or near the point of origin. Patients are rarely diagnosed at this point. But for those fortunate enough to be diagnosed early, several treatment options are available, and they may live several years after a diagnosis.

Diagram shoing the early stages of mesotheliomaClick to expand image

Patients diagnosed with mesothelioma at stages 1 or 2 — also expressed with Roman numerals as stage I and II — have a more favorable prognosis than late-stage patients.

This is mainly because early stages of the cancer respond well to surgery and other traditional treatments.

In stage 1 pleural mesothelioma, tiny tumors develop along the lining of one lung. Stage 2 occurs when the tumors start spreading to the underlying lung tissue or the diaphragm. The lungs and lymph nodes do not contain cancer cells at these early stages.

Stage 1 is the only mesothelioma stage divided into two categories: 1a and 1b. This distinguishes the layer of the pleural lining where tumors begin to form. Tumors on the outer layer closest to the chest wall are given a stage 1a diagnosis. When tumors spread to the inner layer, a diagnosis of stage 1b is given.

Free Mesothelioma Packet

Get a Free Mesothelioma Guide

Have You or a Family Member Been Diagnosed? Get a Free Guide Overnight.

Get Yours Now Get Your Free Mesothelioma Guide
Free Mesothelioma Packet

Treatment Options for Early Stages

Compared to patients in other stages of mesothelioma, patients diagnosed in the early stages have the most treatment options available. A multimodal approach combining surgery, chemotherapy and radiation therapy is recommended for stage 1 and 2 patients in sufficiently good health to handle the aggressive treatment plan. Patients who undergo multimodal therapy may live years beyond the average mesothelioma prognosis.

Surgery

Surgery

The two most common surgery options for mesothelioma patients are a pleurectomy/decortication (P/D) procedure and an extrapleural pneumonectomy (EPP). The recommended surgery will depend on the extent of disease spread, overall health of the patient and the physician's medical opinion.

Learn more about mesothelioma surgeries
Chemotherapy

Chemotherapy

Chemotherapy is usually given after a patient recovers from surgery to kill any remaining cancer cells. Many chemotherapy drugs result in side effects such as fatigue, hair loss and nausea.

Learn more about chemotherapy
Radiation

Radiation Therapy

Doctors traditionally use radiation therapy after surgery to prevent local recurrence. New research suggests that applying radiation therapy before surgery might significantly improve survival rates for many patients. Radiation therapy has also helped manage recurring mesothelioma tumors over extended periods of time. If the cancer returns, your doctor might recommend radiation therapy to keep the tumor under control.

Learn more about radiation therapy
Clinical Trials

Clinical Trials

Eligibility varies for mesothelioma clinical trials, but many early-stage patients may qualify because tumors have not spread throughout the body. These voluntary research studies test chemotherapy drug combinations, immunotherapy treatments and genetic therapies not yet approved by the U.S. Food and Drug Administration for mainstream use.

Learn more about mesothelioma clinical trials

Early Stages of Peritoneal Mesothelioma

There is no definitive staging system for peritoneal mesothelioma, but patients diagnosed before the tumors spread outside the lining of the abdomen have a better outlook.

Peritoneal mesothelioma patients in the early stages of the cancer may benefit from cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy, also known as HIPEC. This multimodal treatment combines the process of heating chemotherapy drugs and delivering them to the abdomen directly following surgery.

Learn more about peritoneal mesothelioma

Find a Mesothelioma Specialist

Get connected with a specialist who can confirm your stage and create a treatment plan for you or a loved one.

Common Symptoms of Early Stages

Mesothelioma is rarely diagnosed in the early stages because symptoms seldom arise that would prompt someone to get medical attention. The cancer has an unusually long latency period, meaning it can take decades after initial asbestos exposure before serious symptoms become noticeable. Stage 1 cases, in particular, often are discovered accidentally.

Symptoms for stage 1 and 2 are mild and often resemble less serious lung conditions such as pneumonia. Stage 1 patients may not experience any symptoms, while those diagnosed with stage 2 may feel chest pain or have difficulty breathing as a result of tumor growth or trapped pleural fluid.

Other common early symptoms include:

  • Fever
  • Body aches
  • Weight loss
  • Shortness of breath
  • Chronic cough

Life Expectancy for Early Stage Mesothelioma

The survival difference between the first two stages isn’t as significant as the variances between stages 2, 3 and 4. Early-stage patients who undergo surgery usually live longer than three years, according to the research of mesothelioma specialists Dr. Raja Flores and Dr. Valeria Rusch.

Mesothelioma is considered a heterogeneous disease, meaning no two cases are alike. Certain patients respond better to treatment and will far surpass the average survival statistics.

Catching the cancer early is a major factor that helps people with stage 1 or 2 live much longer than people with late-stage mesothelioma.

Additional Resources

Get Help Paying for Treatment Learn More
Support Group for Patients Join the Group Now
Free VA Claims Assistance Get Help Now

Matt Mauney is an award-winning journalist with nearly a decade of professional writing experience. He joined Asbestos.com in 2016, and he spends much of his time reading, analyzing and reporting on mesothelioma research articles to ensure people in the mesothelioma community know the latest medical advancements. Prior to joining Asbestos.com, Matt was a reporter at the Orlando Sentinel. If you have a story idea for Matt, please email him at mmauney@asbestos.com.

  1. Cho, B.C.J., Feld, R., Leighl, N., Opitz, I., Anraku, M., Tsao, M., … & de Perrot, M. (2014). A feasibility study evaluating surgery for mesothelioma after radiation therapy: The “SMART” approach for resectable malignant pleural mesothelioma. Journal of Thoracic Oncology, 9(3): 397-402. doi: 10.1097/JTO.0000000000000078
  2. Flores, R.M., & Rusch, V.W. (2005). Staging of mesothelioma. In Pass, H.I., Vogelzang, N.J., & Carbone, M. (Eds.), Malignant Mesothelioma (pp.402-415). New York: Springer.
  3. Rice, D.C. (N/A). Staging of malignant pleural mesothelioma: A guide for patients. Retrieved from http://www.mdanderson.org/patient-and-cancer-information/cancer-information/cancer-types/mesothelioma/mpm%20staging.pdf
  4. Rusch, V.W., & Giroux, D. (2012). Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database. Annals of Cardiothoracic Surgery, 1(4): 438-448. doi: 10.3978/j.issn.2225-319X.2012.11.10
  5. Schil, P.V., Carp, L., Hendriks, J., & Lauwers, P. (2008). Staging of malignant pleural mesothelioma. In Baldi, A. (Ed.), Mesothelioma from Bench Side to Clinic (357-366). New York: Nova Science Publishers, Inc.
  6. Rusch, V. et al. (2001, April 19). A Phase II Trial of Surgical Resection and Adjuvant High-dose Hemithoracic Radiation for Malignant Pleural Mesothelioma. Retrieved from http://www.jtcvsonline.org/article/S0022-5223%2801%2936749-1/pdf
  7. Cho, B.C.J., Feld, R., Leighl, N., Opitz, I., Anraku, M., Tsao, M., … & de Perrot, M. (2014). A feasibility study evaluating surgery for mesothelioma after radiation therapy: The “SMART” approach for resectable malignant pleural mesothelioma. Journal of Thoracic Oncology, 9(3): 397-402. doi: 10.1097/JTO.0000000000000078
  8. Rusch, V.W., & Venkatraman, E. (1999). Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. The Annals of Thoracic Surgery, 68(5): 1799-1804. doi: 10.1016/S0003-4975(99)01038-3
  9. Rusch, V.W., Giroux, D., Kennedy, C., Ruffini, E., Cangir, A.K., Rice, D., … & Meerbeeck, J.P. (2012). Initial analysis of the international association for the study of lung cancer mesothelioma database. Journal of Thoracic Oncology, 7(11): 1631-1639. doi: 10.1097/JTO.0b013e31826915f1
  10. Rusch, V.W., & Venkatraman, E. (1996). The importance of surgical staging in the treatment of malignant pleural mesothelioma. Journal of Cardiovascular Surgery, 111(4): 815-825. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/8614142
  11. Yan, T., Cao, C. and Munkholm-Larsen, S. (2010, February 15). A Pharmacological Review on Intraperitoneal Chemotherapy for Peritoneal Malignancy. World Journal of Gastrointestinal Oncology. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2999163/?tool=pmcentrez
  12. Vogelzang, N.J. et al. (2003). Phase III Study of Pemetrexed in Combination with Cisplatin Versus Cisplatin Alone in Patients with Malignant Pleural Mesothelioma. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12860938
  13. National Comprehensive Cancer Network. (2014). NCCN Guidelines for Patients: Malignant Pleural Mesothelioma. Retrieved from http://www.nccn.org/patients/guidelines/mpm/index.html
  14. Tannapfel, A. (2011). Malignant Mesothelioma: Recent Results in Cancer Research. Springer: Berlin.

Share Our Page

Get Your Free Mesothelioma Guide